摘要
目的基于网络药理学研究柴胡-黄芩药对防治新型冠状病毒肺炎的药物成分,预测作用靶点,并探讨其潜在的作用机制。方法通过中药系统药理学数据库(TCMSP)收集柴胡-黄芩药对的药物成分及相应作用靶点;运用STRING数据库与Cytoscape软件构建"药物成分-靶点"网络和蛋白相互作用网络;通过ClueGO对靶点的基因本体(GO)及KEGG通路进行富集分析。结果以口服生物利用度(OB)和类药性(DL)两个参数为标准,共筛选得到52个药物成分;疾病相关的作用靶点共刷选出41个;通过富集分析得出多条相关的基因本体(GO)功能和KEGG通路。结论该研究结果初步预测了柴胡-黄芩药防治新型冠状病毒肺炎的的主要药物成分、靶点和信号通路,为进一步开展其作用机制的研究提供了新思路和新方向。
Objective To analyze the effective active ingredients of Chaihu(Bupleuri Radix)and Huangqin(Radix Scutellariae)couplet in the treatment of corona virus disease 2019(COVID-19)based on network pharmacology,in order to predict their targets and explore the potential mechanism.Methods Herb ingredients and their corresponding targets were collected from traditional Chinese medicine system pharmacology database(TCMSP).Herb ingredients-targets network and protein interacting network were built by STRING database and Cytoscape software.ClueGO was used to enrich the gene ontology and KEGG pathway of core targets.Results The 52 herb ingredients were screened out based on two parameters[oral bioavailability(OB)and drug-like(DL)].There were 41 targets selected for the research,and a number of corresponding gene ontology(GO)functions and Kyoto Encyclopedin of Genes and Genomes(KEGG)pathways were enriched.Conclusion The results of this study preliminarily predicted the main drug components,targets and signaling pathways of Chaihu(Bupleuri Radix)and Huangqin(Radix Scutellariae)couplet for COVID-19,and provided new ideas and directions for further research on the mechanism of Chaihu(Bupleuri Radix)and Huangqin(Radix Scutellariae)couplet.
作者
束沛
郑忻
席瑞
郑炜东
曲妮妮
SHU Pei;ZHENG Xin;XI Rui;ZHENG Weidong;QU Nini(Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,Liaoning,China)
出处
《辽宁中医药大学学报》
CAS
2021年第1期94-99,共6页
Journal of Liaoning University of Traditional Chinese Medicine
基金
国家中医药管理局中医临床诊疗指南制修订项目(SATCM-2015-BZ[037])
新型冠状病毒肺炎中医药方案的验证、应用和推广研究(2020JH2/10300004)。
关键词
柴胡
黄芩
药对
新型冠状病毒肺炎
分子机制
网络药理学
Chaihu(Bupleuri Radix)
Huangqin(Radix Scutellariae)
couplet medicines
corona virus disease 2019
molecular mechanism
network pharmacology